Land: Europese Unie
Taal: Engels
Bron: EMA (European Medicines Agency)
oritavancin (diphosphate)
Menarini International Operations Luxembourg S.A.
J01XA05
oritavancin
Antibacterials for systemic use,
Soft Tissue Infections; Skin Diseases, Bacterial
Tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and paediatric patients aged 3 months and older (see sections 4.2, 4.4 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Revision: 14
Authorised
2015-03-19
41 B. PACKAGE LEAFLET 42 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT TENKASI 400 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION oritavancin READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or nurse. - If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Tenkasi is and what it is used for 2. What you need to know before you are given Tenkasi 3. How you will be given Tenkasi 4. Possible side effects 5. How to store Tenkasi 6. Contents of the pack and other information 1. WHAT TENKASI IS AND WHAT IT IS USED FOR Tenkasi is an antibiotic that contains the active substance oritavancin. Oritavancin is a type of antibiotic (a lipoglycopeptide antibiotic) that can kill or stop the growth of certain bacteria. Tenkasi is used to treat infections of the skin and underlying tissues. It is for use in adults and paediatric patients aged 3 months and older. Tenkasi can only be used to treat infections caused by bacteria known as Gram-positive bacteria. In mixed infections where other types of bacteria are suspected, your doctor will give you other appropriate antibiotics together with Tenkasi. 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN TENKASI YOU MUST NOT BE GIVEN TENKASI - if you are allergic to oritavancin or any of the other ingredients of this medicine (listed in section 6). - if it is expected that you may need to be given a blood thinning medicine (unfractionated heparin sodium) within 5 days (120 hours) of the dose of Tenkasi. WARNINGS AND PRECAUTIONS Talk to your doctor or nurse before receiving Tenkasi if you: • have ever had an allergic reaction to another glycopeptide antibiotic (such as vancomycin and telavancin) • have developed severe diarrhoea during or following antibiotic treatment in the past • have or Lees het volledige document
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Tenkasi 400 mg powder for concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains oritavancin diphosphate equivalent to 400 mg oritavancin. After reconstitution, 1 ml of the solution contains 10 mg oritavancin. After dilution, 1 ml of the solution for infusion contains 1.2 mg oritavancin. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for concentrate for solution for infusion (powder for concentrate). White to off-white powder. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and paediatric patients aged 3 months and older (see sections 4.2, 4.4 and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults _ 1 200 mg administered as a single dose by intravenous infusion over 3 hours. _Paediatric patients aged 3 months to < 18 years _ 15 mg/kg administered as a single dose by intravenous infusion over 3 hours (maximum 1 200 mg). Please refer to Table 1 for relevant example, and to section 6.6 for further details. TABLE 1: 15 MG/KG BODY WEIGHT DOSE OF ORITAVANCIN: 3-HOUR INFUSION (CONCENTRATION OF 1.2 MG/ML) PATIENT’S WEIGHT (KG) CALCULATED ORITAVANCIN DOSE (MG) TOTAL INFUSION VOLUME (ML) VOLUME OF RECONSTITUTED ORITAVANCIN (ML) VOLUME OF D5W TO ADD TO IV BAG (ML) 5 75 62.5 7.5 55 10 150 125 15 110 15 225 187.5 22.5 165 3 20 300 250 30 220 25 375 312.5 37.5 275 30 450 375 45 330 35 525 437.5 52.5 385 40 600 500 60 440 Special populations _Elderly (≥ 65 years) _ No dose adjustment is required for patients ≥ 65 years of age (see section 5.2). _Renal impairment _ No dose adjustment is needed in patients with mild or moderate renal impairment. Very limited data are available in patients with severe renal impairment. Renal impairment had no c Lees het volledige document